CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation
Cheng‐Yi Wang(Fu Jen Catholic University), Kuen‐Feng Chen(National Taiwan University), Yi‐Ting Tsai(National Yang Ming Chiao Tung University), Yen‐Lin Chen(Tri-Service General Hospital), Ting-Ting Chao(Tri-Service General Hospital), Yuh-Chin T. Huang(Howard Hughes Medical Institute), Chung-Wai Shiau(National Yang Ming Chiao Tung University), Fang-Yu Chang(Fu Jen Catholic University), Hen-I Lin(Fu Jen Catholic University), Chong‐Jen Yu(National Taiwan University Hospital)
Cited by 34
Related Papers
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|The Lancet Oncology|2015|980
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
|Clinical Cancer Research|2015|469
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
|Journal of Clinical Oncology|2023|386
Enhanced Photoluminescence Emission and Thermal Stability from Introduced Cation Disorder in Phosphors
|Journal of the American Chemical Society|2017|244